Phase I studies included 35 patients with relapsed/refractory SCLC or large-cell neuroendocrine tumors, and the ORR was only 14% (5/35); for DLL3-positive patients, the ORR was only 11.8%. This evidence concerns the gene DLL3 and small cell lung carcinoma.